Adavosertib

Generic Name: Adavosertib

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₂N_₈O_₂

CAS Number: 955365-80-7

Unique Ingredient Identifier: K2T6HJX3I3

Background: MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

Clinical Trials

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

First Posted Date: 2016-06-24

Last Posted Date: 2025-01-10

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 455

Registration Number: NCT02813135

Locations: 🇫🇷
CHU Angers, Angers, France
🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
CHU Pellegrin, Bordeaux, France

and more 18 locations

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

Phase 2

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: AZD1775

First Posted Date: 2016-02-23

Last Posted Date: 2018-09-20

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 7

Registration Number: NCT02688907

Locations: 🇰🇷
Keunchil Park, Seoul, Korea, Republic of

Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Early Phase 1

Active, not recruiting

Conditions: Advanced Fallopian Tube Carcinoma
Advanced Ovarian Carcinoma
Advanced Primary Peritoneal Carcinoma
Carcinomatosis
Fallopian Tube High Grade Serous Adenocarcinoma
Primary Peritoneal High Grade Serous Adenocarcinoma
Ovarian High Grade Serous Adenocarcinoma
Stage IIIA Fallopian Tube Cancer AJCC v7
Stage IIIA Ovarian Cancer AJCC v6 and v7
Stage IIIA Primary Peritoneal Cancer AJCC v7

Interventions: Drug: Adavosertib
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-01-20

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 38

Registration Number: NCT02659241

Locations: 🇺🇸
Memorial Hermann Memorial City Medical Center, Houston, Texas, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
MD Anderson West Houston, Houston, Texas, United States

and more 5 locations

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumours

Interventions: Drug: AZD1775
Drug: MEDI4736

First Posted Date: 2015-11-30

Last Posted Date: 2025-05-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 56

Registration Number: NCT02617277

Locations: 🇺🇸
Research Site, Nashville, Tennessee, United States

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Phase 1

Completed

Conditions: Locally Advanced Solid Tumours
Metastatic Solid Tumours
Ovarian Cancer

Interventions: Drug: AZD1775

First Posted Date: 2015-11-20

Last Posted Date: 2023-07-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 62

Registration Number: NCT02610075

Locations: 🇺🇸
Research Site, Nashville, Tennessee, United States

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: AZD1775

First Posted Date: 2015-10-30

Last Posted Date: 2021-03-19

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 24

Registration Number: NCT02593019

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC

Phase 1

Completed

Conditions: Carcinoma, Squamous Cell of Head and Neck

Interventions: Drug: AZD1775
Drug: Cisplatin
Radiation: Intensity Modulated Radiotherapy Treatments

First Posted Date: 2015-10-26

Last Posted Date: 2021-06-29

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 12

Registration Number: NCT02585973

Locations: 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

OLAParib COmbinations

Phase 2

Terminated

Conditions: Cancer

Interventions: Drug: AZD2281
Drug: AZD6738
Drug: AZD5363
Drug: AZD1775

First Posted Date: 2015-10-15

Last Posted Date: 2022-12-28

Lead Sponsor: Joseph Paul Eder

Target Recruit Count: 67

Registration Number: NCT02576444

Locations: 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

Phase 1

Active, not recruiting

Conditions: Muscle Invasive Bladder Cancer

Interventions: Drug: AZD4547
Drug: MEDI4736
Drug: Vistusertib
Drug: AZD9150
Drug: Olaparib
Drug: AZD1775
Drug: Selumetinib

First Posted Date: 2015-09-11

Last Posted Date: 2025-04-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 117

Registration Number: NCT02546661

Locations: 🇬🇧
Research Site, Southampton, United Kingdom

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: AZD1775

First Posted Date: 2015-07-31

Last Posted Date: 2025-04-13

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 42

Registration Number: NCT02513563

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy